DOCSLIB.ORG

21.0692.03000 House Bill No

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
21.0692.03000 House Bill No 21.0692.03000 HOUSE BILL NO. 1213 with Conference Committee Amendments Sixty-seventh Legislative Assembly HOUSE BILL NO. 1213 of North Dakota Introduced by Representatives Westlind, Dobervich, Hanson, M. Ruby, Skroch Senator K. Roers 1 A BILL for an Act to create and enact section 19-24.1-04.1 of the North Dakota Century Code, 2 relating to medical marijuana designated caregivers; to amend and reenact section 19-03.1-01, 3 subsection 5 of section 19-03.1-05, subsection 1 of section 19-03.1-22.2, section 19-03.1-22.3, 4 subsections 1, 7, and 9 of section 19-03.1-23, subsection 12 of section 19-03.4-01, sections 5 19-03.4-03, 19-03.4-04, and 19-24.1-01, subdivision a of subsection 2 of section 19-24.1-03, 6 subsection 3 of section 19-24.1-04, sections 19-24.1-10 and 19-24.1-13, paragraph 2 of 7 subdivision d of subsection 1 of section 19-24.1-14, subdivision a of subsection 1 of section 8 19-24.1-15, subdivision a of subsection 2 of section 19-24.1-16, section 19-24.1-17, 9 subsection 4 of section 19-24.1-18, subsection 2 of section 19-24.1-20, subsection 3 of section 10 19-24.1-26, subsection 2 of section 19-24.1-37, section 19-24.1-39, and subsection 1 of section 11 39-20-01 of the North Dakota Century Code, relating to the medical marijuana program; to 12 provide for a legislative management report; to provide a penalty; and to declare an emergency. 13 BE IT ENACTED BY THE LEGISLATIVE ASSEMBLY OF NORTH DAKOTA: 14 SECTION 1. AMENDMENT. Section 19-03.1-01 of the North Dakota Century Code is 15 amended and reenacted as follows: 16 19-03.1-01. Definitions. 17 As used in this chapter and in chapters 19-03.2 and 19-03.4, unless the context otherwise 18 requires: 19 1. "Administer" means to apply a controlled substance, whether by injection, inhalation, 20 ingestion, or any other means, directly to the body of a patient or research subject by: 21 a. A practitioner or, in the practitioner's presence, by the practitioner's authorized 22 agent; or 23 b. The patient or research subject at the direction and in the presence of the 24 practitioner. Page No. 1 21.0692.03000 Sixty-seventh Legislative Assembly 1 2. "Agent" means an authorized person who acts on behalf of or at the direction of a 2 manufacturer, distributor, or dispenser. It does not include a common or contract 3 carrier, public warehouseman, or employee of the carrier or warehouseman. 4 3. "Anabolic steroids" means any drug or hormonal substance, chemically and 5 pharmacologically related to testosterone, other than estrogens, progestins, and 6 corticosteroids. 7 4. "Board" means the state board of pharmacy. 8 5. "Bureau" means the drug enforcement administration in the United States department 9 of justice or its successor agency. 10 6. "Controlled substance" means a drug, substance, or immediate precursor in schedules 11 I through V as set out in this chapter. 12 7. "Controlled substance analog": 13 a. Means a substance the chemical structure of which is substantially similar to the 14 chemical structure of a controlled substance in a schedule I or II and: 15 (1) Which has a stimulant, depressant, or hallucinogenic effect on the central 16 nervous system which is substantially similar to or greater than the 17 stimulant, depressant, or hallucinogenic effect on the central nervous 18 system of a controlled substance in schedule I or II; or 19 (2) With respect to a particular individual, which the individual represents or 20 intends to have a stimulant, depressant, or hallucinogenic effect on the 21 central nervous system substantially similar to or greater than the stimulant, 22 depressant, or hallucinogenic effect on the central nervous system of a 23 controlled substance in schedule I or II. 24 b. Does not include: 25 (1) A controlled substance; 26 (2) Any substance for which there is an approved new drug application; or 27 (3) With respect to a particular individual, any substance, if an exemption is in 28 effect for investigational use, for that individual, under section 505 of the 29 Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355] to the extent conduct 30 with respect to the substance is pursuant to the exemption. Page No. 2 21.0692.03000 Sixty-seventh Legislative Assembly 1 8. "Counterfeit substance" means a controlled substance which, or the container or 2 labeling of which, without authorization, bears the trademark, trade name, or other 3 identifying mark, imprint, number or device, or any likeness thereof, of a manufacturer, 4 distributor, or dispenser other than the person who in fact manufactured, distributed, or 5 dispensed the substance. 6 9. "Deliver" or "delivery" means the actual, constructive, or attempted transfer from one 7 person to another of a controlled substance whether or not there is an agency 8 relationship. 9 10. "Dispense" means to deliver a controlled substance to an ultimate user or research 10 subject by or pursuant to the lawful order of a practitioner, including the prescribing, 11 administering, packaging, labeling, or compounding necessary to prepare the 12 substance for that delivery. 13 11. "Dispenser" means a practitioner who dispenses. 14 12. "Distribute" means to deliver other than by administering or dispensing a controlled 15 substance. 16 13. "Distributor" means a person who distributes. 17 14. "Drug" means: 18 a. Substances recognized as drugs in the official United States pharmacopeia 19 national formulary, or the official homeopathic pharmacopeia of the United States, 20 or any supplement to any of them; 21 b. Substances intended for use in the diagnosis, cure, mitigation, treatment, or 22 prevention of disease in individuals or animals; 23 c. Substances, other than food, intended to affect the structure or any function of 24 the body of individuals or animals; and 25 d. Substances intended for use as a component of any article specified in 26 subdivision a, b, or c. The term does not include devices or their components, 27 parts, or accessories. 28 15. "Hashish" means the resin extracted from any part of the plant cannabis with or 29 without its adhering plant parts, whether growing or not, and every compound, 30 manufacture, salt, derivative, mixture, or preparation of the resin. 31 16. "Immediate precursor" means a substance: Page No. 3 21.0692.03000 Sixty-seventh Legislative Assembly 1 a. That the board has found to be and by rule designates as being the principal 2 compound commonly used or produced primarily for use in the manufacture of a 3 controlled substance; 4 b. That is an immediate chemical intermediary used or likely to be used in the 5 manufacture of the controlled substance; and 6 c. The control of which is necessary to prevent, curtail, or limit the manufacture of 7 the controlled substance. 8 17.16. "Manufacture" means the production, preparation, propagation, compounding, 9 conversion, or processing of a controlled substance, either directly or indirectly by 10 extraction from substances of natural origin, or independently by means of chemical 11 synthesis, or by a combination of extraction and chemical synthesis and includes any 12 packaging or repackaging of the substance or labeling or relabeling of its container. 13 The term does not include the preparation or compounding of a controlled substance 14 by an individual for the individual's own use or the preparation, compounding, 15 packaging, or labeling of a controlled substance: 16 a. By a practitioner as an incident to the practitioner's administering or dispensing of 17 a controlled substance in the course of the practitioner's professional practice; or 18 b. By a practitioner, or by the practitioner's authorized agent under the practitioner's 19 supervision, for the purpose of, or as an incident to, research, teaching, or 20 chemical analysis and not for sale. 21 18.17. "Marijuana" means all parts of the plant of the genus cannabis sativa L., whether 22 growing or not; the seeds thereof; the resin extracted from any part of the plant; and 23 every compound, manufacture, salt, derivative, mixture, or preparation of the plant, its 24 seeds, or resin. The term does not include the: 25 a. The tetrahydrocannabinol extracted or isolated from the plant; 26 b. The mature stalks of the plant, fiber produced from the stalks, oil or cake made 27 from the seeds of the plant, any other compound, manufacture, salt, derivative, 28 mixture, or preparation of mature stalks, except the resin extracted therefrom, 29 fiber, oil, or cake, or the sterilized seed of the plant which is incapable of 30 germination. The term marijuana does not include hemp as defined in title 4.1.; 31 c. Hemp as defined in chapter 4.1 - 18.1; or Page No. 4 21.0692.03000 Sixty-seventh Legislative Assembly 1 d. A prescription drug approved by the United States food and drug administration 2 under section 505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355]. 3 19.18. "Narcotic drug" means any of the following, whether produced directly or indirectly by 4 extraction from substances of vegetable origin, or independently by means of chemical 5 synthesis, or by a combination of extraction and chemical synthesis: 6 a. Opium and opiate and any salt, compound, derivative, or preparation of opium or 7 opiate. 8 b. Any salt, compound, isomer, derivative, or preparation thereof which is 9 chemically equivalent or identical with any of the substances referred to in 10 subdivision a, but not including the isoquinoline alkaloids of opium.
Load more

Recommended publications
  • Federal Register/Vol. 85, No. 178/Monday, September 14, 2020
    Federal Register / Vol. 85, No. 178 / Monday, September 14, 2020 / Notices 56631 agreements. All non-confidential DEPARTMENT OF JUSTICE ADDRESSES: Written comments should written submissions will be available for be sent to: Drug Enforcement public inspection at the Office of the Drug Enforcement Administration Administration, Attention: DEA Federal Secretary and on EDIS. [Docket No. DEA–713] Register Representative/DPW, 8701 The Commission vote for these Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must determinations took place on September Importer of Controlled Substances Application: Cerilliant Corporation be sent to: Drug Enforcement 8, 2020. Administration, Attn: Administrator, The authority for the Commission’s AGENCY: Drug Enforcement 8701 Morrissette Drive, Springfield, determination is contained in section Administration, Justice. Virginia 22152. All request for a hearing 337 of the Tariff Act of 1930, as ACTION: Notice of application. should also be sent to: (1) Drug amended (19 U.S.C. 1337), and in Part SUMMARY: Cerilliant Corporation has Enforcement Administration, Attn: 210 of the Commission’s Rules of applied to be registered as an importer Hearing Clerk/OALJ, 8701 Morrissette Practice and Procedure (19 CFR part of basic class(es) of controlled Drive, Springfield, Virginia 22152; and 210). substance(s). Refer to Supplemental (2) Drug Enforcement Administration, Attn: DEA Federal Register By order of the Commission. Information listed below for further Representative/DPW, 8701 Morrissette Issued: September 8, 2020. drug information. DATES: Drive, Springfield, Virginia 22152. Lisa Barton, Registered bulk manufacturers of the affected basic class(es), and SUPPLEMENTARY INFORMATION: In Secretary to the Commission. applicants therefore, may file written accordance with 21 CFR 1301.34(a), this [FR Doc.
    [Show full text]
  • 2 Spice English Presentation
    Spice Spice contains no compensatory substances Специи не содержит компенсационные вещества Spice is a mix of herbs (shredded plant material) and manmade chemicals with mind-altering effects. It is often called “synthetic marijuana” because some of the chemicals in it are similar to ones in marijuana; but its effects are sometimes very different from marijuana, and frequently much stronger. It is most often labeled “Not for Human Consumption” and disguised as incense. Eliminationprocess • The synthetic agonists such as THC is fat soluble. • Probably, they are stored as THC in cell membranes. • Some of the chemicals in Spice, however, attach to those receptors more strongly than THC, which could lead to a much stronger and more unpredictable effect. • Additionally, there are many chemicals that remain unidentified in products sold as Spice and it is therefore not clear how they may affect the user. • Moreover, these chemicals are often being changed as the makers of Spice alter them to avoid the products being illegal. • To dissolve the Spice crystals Acetone is used endocannabinoids synhtetic THC cannabinoids CB1 and CB2 agonister Binds to cannabinoidreceptor CB1 CB2 - In the brain -in the immune system Decreased avtivity in the cell ____________________ Maria Ellgren Since some of the compounds have a longer toxic effects compared to naturally THC, as reported: • negative effects that often occur the day after consumption, as a general hangover , but without nausea, mentally slow, confused, distracted, impairment of long and short term memory • Other reports mention the qualitative impairment of cognitive processes and emotional functioning, like all the oxygen leaves the brain.
    [Show full text]
  • Hb 185 an Act Listing Synthetic
    62nd Legislature HB0185 AN ACT LISTING SYNTHETIC MARIJUANA AND SALVIA AS DANGEROUS DRUGS; REQUIRING RULEMAKING BY THE DEPARTMENT OF PUBLIC HEALTH AND HUMAN SERVICES; PROVIDING PENALTIES; AMENDING SECTIONS 44-12-102, 45-9-101, 45-9-102, 45-9-110, 50-31-306, 50-31-310, AND 50-32-222, MCA; AND PROVIDING AN IMMEDIATE EFFECTIVE DATE. BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MONTANA: Section 1. Section 44-12-102, MCA, is amended to read: "44-12-102. Things subject to forfeiture. (1) The following are subject to forfeiture: (a) all controlled substances that have been manufactured, distributed, prepared, cultivated, compounded, processed, or possessed in violation of Title 45, chapter 9; (b) all money, raw materials, products, and equipment of any kind that are used or intended for use in manufacturing, preparing, cultivating, compounding, processing, delivering, importing, or exporting any controlled substance in violation of Title 45, chapter 9, except items used or intended for use in connection with quantities of marijuana in amounts less than 60 grams; (c) except as provided in subsection (2)(d), all property that is used or intended for use as a container for anything enumerated in subsection (1)(a) or (1)(b); (d) except as provided in subsection (2), all conveyances, including aircraft, vehicles, and vessels, that are used or intended for use in any manner to facilitate the commission of a violation of Title 45, chapter 9; (e) all books, records, and research products and materials, including formulas, microfilm, tapes, and data,
    [Show full text]
  • Introduced B.,Byhansen, 16
    LB301 LB301 2021 2021 LEGISLATURE OF NEBRASKA ONE HUNDRED SEVENTH LEGISLATURE FIRST SESSION LEGISLATIVE BILL 301 Introduced by Hansen, B., 16. Read first time January 12, 2021 Committee: Judiciary 1 A BILL FOR AN ACT relating to the Uniform Controlled Substances Act; to 2 amend sections 28-401, 28-405, and 28-416, Revised Statutes 3 Cumulative Supplement, 2020; to redefine terms; to change drug 4 schedules and adopt federal drug provisions; to change a penalty 5 provision; and to repeal the original sections. 6 Be it enacted by the people of the State of Nebraska, -1- LB301 LB301 2021 2021 1 Section 1. Section 28-401, Revised Statutes Cumulative Supplement, 2 2020, is amended to read: 3 28-401 As used in the Uniform Controlled Substances Act, unless the 4 context otherwise requires: 5 (1) Administer means to directly apply a controlled substance by 6 injection, inhalation, ingestion, or any other means to the body of a 7 patient or research subject; 8 (2) Agent means an authorized person who acts on behalf of or at the 9 direction of another person but does not include a common or contract 10 carrier, public warehouse keeper, or employee of a carrier or warehouse 11 keeper; 12 (3) Administration means the Drug Enforcement Administration of the 13 United States Department of Justice; 14 (4) Controlled substance means a drug, biological, substance, or 15 immediate precursor in Schedules I through V of section 28-405. 16 Controlled substance does not include distilled spirits, wine, malt 17 beverages, tobacco, hemp, or any nonnarcotic substance if such substance 18 may, under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.
    [Show full text]
  • Substances in Penalty Group Two
    Substances in Penalty Group Two Sec. 481.103. PENALTY GROUP 2. (a) Penalty Group 2 consists of: (1) any quantity of the following hallucinogenic substances, their salts, isomers, and salts of isomers, unless specifically excepted, if the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation: alpha-ethyltryptamine; 4-bromo-2, 5-dimethoxyamphetamine (some trade or other names: 4- bromo- 2, 5-dimethoxy-alpha-methylphenethylamine; 4-bromo-2, 5-DMA); 4-bromo-2, 5-dimethoxyphenethylamine; Bufotenine (some trade and other names: 3-(beta-Dimethylaminoethyl) - 5-hydroxyindole; 3-(2-dimethylaminoethyl)-5- indolol; N, N- dimethylserotonin; 5-hydroxy-N, N-dimethyltryptamine; mappine); Diethyltryptamine (some trade and other names: N, N-Diethyltryptamine, DET); 2, 5-dimethoxyamphetamine (some trade or other names: 2, 5- dimethoxy- alpha-methylphenethylamine; 2, 5-DMA); 2, 5-dimethoxy-4-ethylamphetamine ( trade or other name : DOET); 2, 5-dimethoxy-4-(n)-propylthiophenethylamine (trade or other name: 2C-T-7); Dimethyltryptamine ( trade or other name : DMT); Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. Food and Drug Administration approved drug product (some trade or other names for Dronabinol: (a6aR-trans)-6a,7,8,10a-tetrahydro- 6,6, 9-trimethyl-3-pentyl-6H- dibenzo [b,d]pyran-1-ol or (-)-delta-9-(trans)- tetrahydrocannabinol); Ethylamine Analog of Phencyclidine (some trade or other names: N- ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl) ethylamine,
    [Show full text]
  • 16.19.20 Nmac 1 Title 16 Occupational And
    TITLE 16 OCCUPATIONAL AND PROFESSIONAL LICENSING CHAPTER 19 PHARMACISTS PART 20 CONTROLLED SUBSTANCES 16.19.20.1 ISSUING AGENCY: Regulation and Licensing Department - Board of Pharmacy. [16.19.20.1 NMAC - Rp 16.19.20.1 NMAC, 06-26-2018] 16.19.20.2 SCOPE: All persons or entities that manufacture, distribute, dispense, administer, prescribe, deliver, analyze, or conduct research using controlled substances. [16.19.20.2 NMAC - Rp 16.19.20.2 NMAC, 06-26-2018] 16.19.20.3 STATUTORY AUTHORITY: Section 30-31-11 of the Controlled Substances Act, 30-31-1 through 30-31-42 NMSA 1978, authorizes the board of pharmacy to promulgate regulations and charge reasonable fees for the registration and control of the manufacture, distribution and dispensing of controlled substances. [16.19.20.3 NMAC - Rp 16.19.20.3 NMAC, 06-26-2018] 16.19.20.4 DURATION: Permanent. [16.19.20.4 NMAC - Rp 16.19.20.4 NMAC, 06-26-2018] 16.19.20.5 EFFECTIVE DATE: June 26, 2018, unless a different date is cited at the end of a section. [16.19.20.5 NMAC - Rp 16.19.20.5 NMAC, 06-26-2018] 16.19.20.6 OBJECTIVE: The objective of Part 20 of Chapter 19 is to protect the public health and welfare of the citizens of New Mexico by controlling and monitoring access to controlled substances and to give notice of the board’s designation of particular substances as controlled substances. [16.19.20.6 NMAC - Rp 16.19.20.6 NMAC, 06-26-2018] 16.19.20.7 DEFINITIONS: [RESERVED] [16.19.20.7 NMAC - Rp 16.19.20.7 NMAC, 06-26-2018] 16.19.20.8 REGISTRATION REQUIREMENTS: Persons required to register: A.
    [Show full text]
  • Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)
    Model Scheduling New/Novel Psychoactive Substances Act (Third Edition) July 1, 2019. This project was supported by Grant No. G1799ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact NAMSDL at [email protected] or (703) 229-4954 with any questions about the Model Language. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: NATIONAL ALLIANCE FOR MODEL STATE DRUG 1 LAWS, 1335 North Front Street, First Floor, Harrisburg, PA, 17102-2629. Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)1 Table of Contents 3 Policy Statement and Background 5 Highlights 6 Section I – Short Title 6 Section II – Purpose 6 Section III – Synthetic Cannabinoids 13 Section IV – Substituted Cathinones 19 Section V – Substituted Phenethylamines 23 Section VI – N-benzyl Phenethylamine Compounds 25 Section VII – Substituted Tryptamines 28 Section VIII – Substituted Phenylcyclohexylamines 30 Section IX – Fentanyl Derivatives 39 Section X – Unclassified NPS 43 Appendix 1 Second edition published in September 2018; first edition published in 2014. Content in red bold first added in third edition. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws.
    [Show full text]
  • 83(R) Hb 1333
    By:AAPerry, et al. H.B.ANo.A1333 Substitute the following forAH.B.ANo.A1333: By:AAHerrero C.S.H.B.ANo.A1333 A BILL TO BE ENTITLED 1 AN ACT 2 relating to the designation of certain synthetic compounds to 3 Penalty Group 2 or 2-A of the Texas Controlled Substances Act. 4 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: 5 SECTIONA1.AASections 481.002(5) and (6), Health and Safety 6 Code, are amended to read as follows: 7 (5)AA"Controlled substance" means a substance, 8 including a drug, an adulterant, and a dilutant, listed in 9 Schedules I through V or Penalty Group [Groups] 1, 1-A, [or] 2, 2-A, 10 3, or [through] 4. The term includes the aggregate weight of any 11 mixture, solution, or other substance containing a controlled 12 substance. 13 (6)AA"Controlled substance analogue" means: 14 (A)AAa substance with a chemical structure 15 substantially similar to the chemical structure of a controlled 16 substance in Schedule I or II or Penalty Group 1, 1-A, [or] 2, or 17 2-A; or 18 (B)AAa substance specifically designed to produce 19 an effect substantially similar to, or greater than, the effect of a 20 controlled substance in Schedule I or II or Penalty Group 1, 1-A, 21 [or] 2, or 2-A. 22 SECTIONA2.AASection 481.103(a), Health and Safety Code, is 23 amended to read as follows: 24 (a)AAPenalty Group 2 consists of: 83R13830 JSC-F 1 C.S.H.B.ANo.A1333 1 (1)AAany quantity of the following hallucinogenic 2 substances, their salts, isomers, and salts of isomers, unless 3 specifically excepted, if the existence of these salts, isomers, 4 and
    [Show full text]
  • Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority
    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them, and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
    [Show full text]
  • PRODUCT INFORMATION FDU-PB-22 Item No
    PRODUCT INFORMATION FDU-PB-22 Item No. 14968 CAS Registry No.: 1883284-94-3 F Formal Name: ​1-[(4-fluorophenyl)methyl]- 1H-indole-3-carboxylic acid, N O 1-naphthalenyl ester MF: C26H18FNO2 O FW: 395.4 Purity: ≥98% UV/Vis.: λmax: 220, 294 nm Supplied as: A crystalline solid Storage: -20°C Stability: As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly Description Several cannabimimetic quinolinyl carboxylates (PB-22, Item No. 14096 and BB-22, Item No. 14099) and cannabimimetic carboxamide derivatives (ADB-FUBINACA, Item No. 14292 and ADBICA, Item No. 14293) have been identified as designer drugs in illegal products.1 FDU-PB-22 is a derivative of PB-22 in which the pentyl side chain is replaced by a 4-fluorobenzyl group, a functional group also found in indazole-based synthetic cannabinoids such as ADB-FUBINACA. Additionally, the 8-quinolinol is replaced by a naphthalene group, similar to the structure of AM2201(Item No. 10707).1-3 The physiological and toxicological properties of this compound are not known. This product is intended for forensic and research applications. References 1. Uchiyama, N., Matsuda, S., Kawamura, M., et al. Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products. Forensic Toxicol. 31(2), 223-240 (2013). 2. Uchiyama, N., Matsuda, S., Wakana, D., et al. New cannabimimetic indazole derivatives, N-(1-amino- 3methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3- methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products.
    [Show full text]
  • Phase I in Vitro Metabolic Profiling of the Synthetic Cannabinoid
    H OH metabolites OH Article Phase I In Vitro Metabolic Profiling of the Synthetic Cannabinoid Receptor Agonists CUMYL-THPINACA and ADAMANTYL-THPINACA Manuela Carla Monti , Eva Scheurer and Katja Mercer-Chalmers-Bender * Institute of Forensic Medicine, Department of Biomedical Engineering, University of Basel, 4056 Basel, Switzerland; [email protected] (M.C.M.); [email protected] (E.S.) * Correspondence: [email protected] Abstract: Synthetic cannabinoid receptor agonists (SCRAs) remain popular drugs of abuse. As many SCRAs are known to be mostly metabolized, in vitro phase I metabolic profiling was conducted of the two indazole-3-carboxamide SCRAs: CUMYL-THPINACA and ADAMANTYL-THPINACA. Both compounds were incubated using pooled human liver microsomes. The sample clean-up consisted of solid phase extraction, followed by analysis using liquid chromatography coupled to a high resolution mass spectrometer. In silico-assisted metabolite identification and structure elucidation with the data-mining software Compound Discoverer was applied. Overall, 28 metabolites were detected for CUMYL-THPINACA and 13 metabolites for ADAMATYL-THPINACA. Various mono-, di-, and tri-hydroxylated metabolites were detected. For each SCRA, an abundant and characteristic di-hydroxylated metabolite was identified as a possible in vivo biomarker for screening methods. Metabolizing cytochrome P450 isoenzymes were investigated via incubation of relevant recombinant liver enzymes. The involvement of mainly CYP3A4 and CYP3A5 in the metabolism of both substances Citation: Monti, M.C.; Scheurer, E.; were noted, and for CUMYL-THPINACA the additional involvement (to a lesser extent) of CYP2C8, Mercer-Chalmers-Bender, K. Phase I In Vitro Metabolic Profiling of the CYP2C9, and CYP2C19 was observed.
    [Show full text]
  • Critical Review Report: ADB-FUBINACA
    Critical Review Report: ADB-FUBINACA Expert Committee on Drug Dependence Forty-first Meeting Geneva, 12-16 November 2018 This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization 41st ECDD (2018): ADB-FUBINACA © World Health Organization 2018 All rights reserved. This is an advance copy distributed to the participants of the 41st Expert Committee on Drug Dependence, before it has been formally published by the World Health Organization. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.
    [Show full text]